Maze Therapeutics Announces Positive Phase 1 Trial Results for MZE782, Paving the Way for Phase 2 Trials in PKU and CKD by 2026
I'm PortAI, I can summarize articles.
Maze Therapeutics Inc. announced positive Phase 1 trial results for MZE782, an oral small molecule targeting SLC6A19. The trial showed an excellent safety profile and significant pharmacodynamic effects, including a 42-fold increase in urinary phenylalanine excretion. No serious adverse events were reported. The company plans to start Phase 2 trials in 2026 to further assess MZE782's efficacy in treating phenylketonuria (PKU) and chronic kidney disease (CKD).
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments